Nottingham Trent University

Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at the American Society of Hematology’s (ASH) 64th Annual Meeting

Retrieved on: 
Sunday, December 11, 2022
Research, Finance, Clinical Trials, Professional Services, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Royal College of Pathologists, NK, Glucose, Immunotherapy, Fibroblast, Nottingham Trent University, Society, TME, Patient, Cancer, Allotransplantation, CIML, Cell, Cryopreservation, Tumor microenvironment, Bone marrow, AML, Safety, Acute myeloid leukemia, Natural killer T cell, FRSB, ASH, Acute leukemia, Phenotype, Pharmaceutical industry, Vaccine, Medical imaging, Fine chemical

These data functionally characterizing the anti-tumor properties of WU-NK-101 are highly encouraging and support the potential for WU-NK-101 as a treatment for relapsed/refractory (r/r) AML.

Key Points: 
  • These data functionally characterizing the anti-tumor properties of WU-NK-101 are highly encouraging and support the potential for WU-NK-101 as a treatment for relapsed/refractory (r/r) AML.
  • Further, the identification of a TME immune signature highly predictive of response may be an impactful tool to support future clinical studies.
  • These data further validate our approach deploying WU-NK-101 for AML, said Jan Davidson-Moncada, M.D., Ph.D., Chief Medical Officer of Wugen.
  • In early clinical studies, memory NK cells have already demonstrated impressive efficacy against AML.

Ara Partners Hires David Touhey as Managing Director of Portfolio Services Group

Retrieved on: 
Tuesday, September 20, 2022
Partner, EPC, Technological University Dublin, Science and technology in Asia, Engineering, Nottingham Trent University, Executive, Science, Food, Renewable energy, Cherington

HOUSTON, Sept. 20, 2022 /PRNewswire/ -- Ara Partners ("Ara"), a private equity firm specializing in industrial decarbonization investments, today announced that David Touhey has joined as Managing Director of the firm's Portfolio Services Group. Mr. Touhey has more than 20 years of experience in project development and optimization in the industrial sector.

Key Points: 
  • HOUSTON, Sept. 20, 2022 /PRNewswire/ -- Ara Partners ("Ara"), a private equity firm specializing in industrial decarbonization investments, today announced that David Touhey has joined as Managing Director of the firm's Portfolio Services Group.
  • "The addition of David to the Ara team underlines our critical focus on project execution across our growing portfolio," saidCharles Cherington, a Managing Partner at Ara.
  • "We are thrilled to welcome David to a leadership role in Ara's Portfolio Services Group," addedTroy Thacker, a Managing Partner at Ara.
  • Prior to joining Ara, Mr. Touhey was the Executive Vice President for Kent, a global EPC, operations, and maintenance business.

Ara Partners Hires David Touhey as Managing Director of Portfolio Services Group

Retrieved on: 
Tuesday, September 20, 2022
Partner, EPC, Technological University Dublin, Science and technology in Asia, Engineering, Nottingham Trent University, Executive, Science, Food, Renewable energy, Cherington

HOUSTON, Sept. 20, 2022 /PRNewswire/ -- Ara Partners ("Ara"), a private equity firm specializing in industrial decarbonization investments, today announced that David Touhey has joined as Managing Director of the firm's Portfolio Services Group. Mr. Touhey has more than 20 years of experience in project development and optimization in the industrial sector.

Key Points: 
  • HOUSTON, Sept. 20, 2022 /PRNewswire/ -- Ara Partners ("Ara"), a private equity firm specializing in industrial decarbonization investments, today announced that David Touhey has joined as Managing Director of the firm's Portfolio Services Group.
  • "The addition of David to the Ara team underlines our critical focus on project execution across our growing portfolio," saidCharles Cherington, a Managing Partner at Ara.
  • "We are thrilled to welcome David to a leadership role in Ara's Portfolio Services Group," addedTroy Thacker, a Managing Partner at Ara.
  • Prior to joining Ara, Mr. Touhey was the Executive Vice President for Kent, a global EPC, operations, and maintenance business.

Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022

Retrieved on: 
Saturday, September 10, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Time, Acute myeloid leukemia, Acute leukemia, Phenotype, AML, Nottingham Trent University, TME, Royal College of Pathologists, NK, Oncology, Congress, FRSB, Cancer, Immunotherapy, European Society of Gene and Cell Therapy, Neutralizing antibody, European Society for Medical Oncology, ESMO, Hematological Cancer Research Investment and Education Act, Memory, EDT, Neoplasm, ADCC, CIML, Paris Expo Porte de Versailles, Medical imaging, Vaccine

Todays findings are an important step forward as we continue to advance WU-NK-101 into clinical development for both solid tumors and acute myeloid leukemia (AML).

Key Points: 
  • Todays findings are an important step forward as we continue to advance WU-NK-101 into clinical development for both solid tumors and acute myeloid leukemia (AML).
  • These findings are highly promising and suggest that memory NK cells can circumvent these challenges, with broad potential therapeutic applications for solid tumors.
  • These data suggest that WU-NK-101 may overcome the current limitations of adoptive cellular therapies and support its clinical development in the solid tumor setting.
  • Wugen is applying its proprietary MonetaTM platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer.

Schulte Roth & Zabel Expands Investment Management Practice with Addition of Leonora Shalet

Retrieved on: 
Monday, May 23, 2022
Employment, Schulte Roth & Zabel, Investment, LL.B, Insurance, University, Bankruptcy, Associate, Trust, Real estate investment trust, Industry, SRZ, Daiwa Securities Capital Markets Co. Ltd., Intellectual property, Blockchain, Compliance, Organization, Special counsel, Nottingham Trent University, ESG, Financial services

NEW YORK, May 23, 2022 /PRNewswire/ -- Schulte Roth & Zabel (SRZ) is pleasedto announce that Leonora Shalet has rejoined the firm as a partner in the firm's New York office and member of the Investment Management Practice.

Key Points: 
  • NEW YORK, May 23, 2022 /PRNewswire/ -- Schulte Roth & Zabel (SRZ) is pleasedto announce that Leonora Shalet has rejoined the firm as a partner in the firm's New York office and member of the Investment Management Practice.
  • "Schulte is known to have the industry's preeminent private funds practice, and I am absolutely delighted to rejoin the team," said Leonora.
  • "Leonora exemplifies the high level of talent we are attracting to Schulte Roth & Zabel," said David Efron, co-managing partner of SRZ and Investment ManagementGroup partner.
  • Schulte Roth & Zabel LLP ( www.srz.com ) is a full-service law firm with offices in New York, Washington, DC and London.

Artio Medical Welcomes New R&D Leaders and Accelerates Development of Amplifi™ Vein Dilation System

Retrieved on: 
Thursday, February 24, 2022
Medtronic, Red blood cell, Medicare, Moses Austin, Griffith, Cardiology, Tansley, Center, University, Medicaid, Industry, Arteriovenous fistula, Mechanical engineering, Centers for Medicare & Medicaid Services, Sale, BS, National Kidney Foundation, Bachelor of Science, Mechanical, Senior, Arm, Multimedia, Clinical research, Tamez, Stroke, Griffith University, Patient, Blood, Patent, Von Willebrand factor, Hemodynamics, MD, CEO, Nottingham Trent University, Doctor of Philosophy, AVF, Ioctl, Medical imaging, Medical device, Engineering

"We are pleased to welcome Dan and Geoff to the Artio team at this important time," said F. Nicholas Franano, MD, President and CEO of Artio Medical.

Key Points: 
  • "We are pleased to welcome Dan and Geoff to the Artio team at this important time," said F. Nicholas Franano, MD, President and CEO of Artio Medical.
  • Tamez joins Artio with over 25 years of medical device experience, including deep domain expertise in blood pumps and mechanical circulatory support.
  • Artio Medical is a medical device company committed to developing innovative products for the treatment of peripheral vascular, neurovascular, and cardiology diseases.
  • Amplifi Vein Dilation System is not available for commercial sale in US.

ComplyAdvantage Names Nabeel Vilcassim CFO and Oliver Furniss CPO As The RegTech Innovator Prepares For Record Growth In 2022

Retrieved on: 
Thursday, January 20, 2022
Other Professional Services, Software, Finance, Consulting, Banking, Data Management, Professional Services, Technology, Financial technology, Face, Ideation, Moelis & Company, Mobile backend as a service, HTB, CPO, M&A, Dojo, COO, Electricity, EMEA, Growth, Citigroup, AML, Index Ventures, Â, Economics, Corruption, Science and technology in Asia, Intelligence, ARR, Clearing house (finance), Ellipse, Nottingham Trent University, Wise, Company, Xero, CFO, Electronic, Multimedia, Risk, Kaizen, ComplyAdvantage, TransferMate, Goldman Sachs, Cluj-Napoca, Balderton Capital, Compliance, Imperial College London, Gemini, Machine learning, Management, Cryptocurrency, Security (finance), Audit, Drug

For 2022, the company anticipates its growth momentum to continue to hit record levels and expects to grow the team to ~500 employees by year end.

Key Points: 
  • For 2022, the company anticipates its growth momentum to continue to hit record levels and expects to grow the team to ~500 employees by year end.
  • As CFO, Nabeel will oversee all areas of the finance organisation including the finance function, corporate development, compliance, and investor relations.
  • I chose to join ComplyAdvantage because of the exciting mission the company is working on, said Oliver Furniss.
  • "And now with the new additions of Nabeel and Oliver, the company is poised to make 2022 another breakthrough year.

Slone Partners Places Jonathan Birchall as Chief Commercial Officer at PhaseBio Pharmaceuticals

Retrieved on: 
Tuesday, November 30, 2021
People, Genentech, Regulation of tobacco by the U.S. Food and Drug Administration, CEO, Business administration, Marketing, Precision medicine, MBA, University, Leadership, History, Bachelor of Science, Master of Science, CRO, Open University, United Kingdom, Biotechnology, Sanofi, Knowledge, FDA, Master of Business Administration, Nottingham Trent University, Food, Pharmaceutical industry, Fine chemical, Management

SOUTH RIDING, Va., Nov. 30, 2021 /PRNewswire-PRWeb/ -- Slone Partners , a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Jonathan Birchall as Chief Commercial Officer at PhaseBio Pharmaceuticals , a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases.

Key Points: 
  • SOUTH RIDING, Va., Nov. 30, 2021 /PRNewswire-PRWeb/ -- Slone Partners , a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Jonathan Birchall as Chief Commercial Officer at PhaseBio Pharmaceuticals , a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases.
  • "Jonathan brings to PhaseBio deep commercial expertise in the critical-care setting, which he gained through his leadership of the thrombolytics franchise at Genentech," said Jonathan P. Mow , Chief Executive Officer of PhaseBio.
  • Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations People Are Our Science.
  • To learn more about Slone Partners' value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.

Kindred's revenue from harmful gambling 3.3 per cent in the third quarter

Retrieved on: 
Monday, October 25, 2021
Online, Responsible gambling, Group, Gambling in Thailand, Kindred Group, Publishing, Cluster analysis, Secondary research, Kindred, Gambling, CEO, Nottingham Trent University, Doctor of Philosophy, Online gambling

VALLETTA, Malta, Oct. 25, 2021 /PRNewswire/ --  Kindred Group plc (Kindred) is committed to transform gambling by being a trusted source of entertainment that contributes positively to society. Therefore, Kindred has set an ambition to reach zero per cent of revenue from harmful gambling by the end of 2023 and to report this on a quarterly basis. The purpose is to be transparent, contribute to a fact-based dialogue about harmful gambling, and raise awareness of the Group's sustainability work. For the third quarter of 2021, the share of revenue from harmful gambling decreased to 3.3 per cent from 4.3 per cent in Q2 2021. 

Key Points: 
  • "We are pleased to see that the percentage of revenue coming from harmful gambling has decreased.
  • Whilst we welcome this decrease, we do understand that we still have to work hard to further decrease this number.
  • Read more about the study 'Applying the DSM-5 Criteria for Gambling Disorder to Online Gambling Account-Based Tracking Data: An Empirical Study Utilizing Cluster Analysis' here: https://bit.ly/3BX7ryH
    Kindred has an ambition to have zero per cent revenue from harmful gambling on its platform by 2023.
  • Since February 2021, the Group reports its share of revenuederived from harmful gambling.

Kindred's revenue from harmful gambling 3.3 per cent in the third quarter

Retrieved on: 
Monday, October 25, 2021
Online, Responsible gambling, Group, Gambling in Thailand, Kindred Group, Publishing, Cluster analysis, Secondary research, Kindred, Gambling, CEO, Nottingham Trent University, Doctor of Philosophy, Online gambling

"We are pleased to see that the percentage of revenue coming from harmful gambling has decreased.

Key Points: 
  • "We are pleased to see that the percentage of revenue coming from harmful gambling has decreased.
  • Whilst we welcome this decrease, we do understand that we still have to work hard to further decrease this number.
  • Read more about the study 'Applying the DSM-5 Criteria for Gambling Disorder to Online Gambling Account-Based Tracking Data: An Empirical Study Utilizing Cluster Analysis' here: https://bit.ly/3BX7ryH
    Kindred has an ambition to have zero per cent revenue from harmful gambling on its platform by 2023.
  • Since February 2021, the Group reports its share of revenuederived from harmful gambling.